Sakar Healthcare Ltd (SAKAR) is currently trading at 1,158.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sakar Healthcare Limited is an India‑based integrated pharmaceutical manufacturer and CDMO offering API‑to‑FDF capabilities across oral solids, sterile injectables (liquids and lyophilised), oral liquids and oncology formulations, operating EU‑GMP and WHO‑GMP certified facilities and supplying global partners and own‑brand exports to 60+ countries. Sakar has deliberately repositioned toward oncology as a value driver: the Bavla facility is EU‑GMP approved, vertically integrates API and finished dosage manufacturing, and currently lists 55 oncology molecules developed with 32 dossiers ready for launch and eleven marketing authorisations granted, signalling a step‑change in product complexity and margin profile. Q3FY26 displayed a sharp operational inflection: consolidated revenue rose 62% YoY to INR 70.34 crore, EBITDA grew 58% to INR 18.59 crore with 26% margins, and PAT more than doubled to INR 10.25 crore, reflecting improved mix, higher own‑brand exports and early commercialisation of oncology dossiers contributing to near‑term profitability expansion. Commercial traction is supported by deep industry partnerships and technology transfers: Sakar disclosed inclusion as a manufacturing source for Accord/Intas Imatinib supplies, ten tech‑transfer products in process, longstanding client relationships with major Indian multinationals and a shift to own‑brand exports now contributing roughly 70% of revenues, improving margin resilience. Sakar emphasizes sustainable process technology and backward integration: investments in flow chemistry, green chemistry principles, CEP/DMF development and API capacity aim to reduce sourcing risk and improve gross margins, while management expects maintenance capex only going forward after significant FY26 capex spend that completed oncology readiness.

Over the past 52 weeks, Sakar Healthcare Ltd has traded between a low of ₹330.00 and a high of ₹1,211.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sakar Healthcare Ltd has a market capitalization of approximately 2,577.76. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sakar Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 71.43 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,577.76 Cr, Sakar Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sakar Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sakar Healthcare Ltd is 71.43. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.